Biomea Fusion announced that it is an investigational novel covalent menin inhibitor developed to regenerate insulin-producing beta cells with the aim to cure diabetes; At Week 26, 22 weeks after the last dose of BMF-219, participants in the 100 mg QD (without food) cohort saw an improved placebo adjusted mean reduction in HbA1c of 0.8% (compared to a 0.7% placebo adjusted mean reduction in HssA1c at Week 4); Observed HbA1C reduction was supported by an increase from baseline in placebo adjusted mean HOMA-B (+270%) and in mean stimulated C-peptide AUC (+22%) at Week 26 in responders (defined as HbA1c reduction 0.5% at Week 26) with baseline below the HOMA-B upper limit of normal (2, and had poorly controlled diabetes (HbA1c 7.0% and 10%). At baseline, diabetic patients in Cohorts 2 and 3 had a mean HbA1c of 8.0% and 8.1%, respectively.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
10.65 USD | -6.91% | -13.77% | -26.65% |
02/05 | Biomea Fusion, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
03/04 | North American Morning Briefing : Powell Awaited -2- | DJ |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-26.65% | 38Cr | |
+17.96% | 4.5TCr | |
+1.17% | 4.26TCr | |
+46.56% | 4.18TCr | |
-4.27% | 2.9TCr | |
+11.42% | 2.61TCr | |
-21.39% | 1.9TCr | |
+4.86% | 1.28TCr | |
+27.29% | 1.21TCr | |
-3.50% | 1.18TCr |
- Stock Market
- Equities
- BMEA Stock
- News Biomea Fusion, Inc.
- Biomea Fusion, Inc. Presents Long-Term Follow-Up Data Showing Improved Glycemic Control After 22 Weeks Off Treatment in Ongoing Phase II Study (COvalent-111) of BMF-219 in Adults with Type 2 Diabetes in A Poster Presentation at the World Congress Insulin Resistance, Diabetes